Vera Therapeutics EBIT

Vera Therapeutics (VERA) currently reports a EBIT of $-400M as of June 2026. That compares with $-220M in the prior-year period — down 80.2% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Vera Therapeutics's EBIT history and peer comparisons.

Vera Therapeutics's EBIT decreased from $-220M to $-400M — a 80.2% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Vera Therapeutics's EBIT of $-400M is lower than the Healthcare sector average of $23B. That is roughly 101.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Vera Therapeutics reported $-400M in EBIT as of June 2026. That compares with $-220M in the prior-year period — down 80.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-400M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Vera Therapeutics, and consider following VERA for alerts when major investors trade the stock.